FindTrial
Sign In

nanoparticle albumin-bound paclitaxel

DRUG10 trials

Sponsors

Peking University, Yanqiao Zhang, Chinese Academy of Medical Sciences, Zhejiang University, Chinese PLA General Hospital

Conditions

Advanced Pancreatic CancerGastric AdenocarcinomaMetastatic Breast CancerNon Small Cell Lung CancerPancreatic CancerSquamous Cell Carcinoma of EsophagusSquamous Cell Carcinoma of Lung

Phase 1

Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients
CompletedNCT01336062
Peking UniversityGastric Adenocarcinoma
Start: 2011-04-30End: 2012-12-31Updated: 2015-05-19
An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer
CompletedNCT03505528
EpiAxis TherapeuticsMetastatic Breast Cancer
Start: 2017-08-17End: 2019-10-30Updated: 2019-11-13
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Not yet recruitingNCT07444541
Anova Innovation LimitedPancreatic Cancer
Start: 2026-03-01End: 2028-12-01Target: 84Updated: 2026-03-03

Phase 2

Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients
NCT01641783
Yanqiao ZhangGastric Adenocarcinoma
Start: 2012-07-31End: 2013-12-31Target: 40Updated: 2012-07-17
Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer
NCT01969955
Chinese Academy of Medical SciencesSquamous Cell Carcinoma of Lung
Start: 2013-09-30End: 2015-06-30Target: 50Updated: 2014-04-25
Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer
NCT02016209
Zhejiang UniversityNon Small Cell Lung Cancer
Start: 2014-01-31End: 2016-03-31Target: 30Updated: 2013-12-19
Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus
WithdrawnNCT02033538
Zhejiang UniversitySquamous Cell Carcinoma of Esophagus
Start: 2014-01-31End: 2016-12-31Updated: 2015-03-05
Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer
NCT02124317
Chinese PLA General HospitalAdvanced Pancreatic Cancer
Start: 2014-04-30End: 2017-05-31Updated: 2016-12-22
Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer
NCT02135822
Chinese PLA General HospitalAdvanced Pancreatic Cancer
Start: 2014-05-31End: 2015-12-31Target: 30Updated: 2014-05-16
Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer
NCT03636308
Peking UniversityPancreatic Cancer
Start: 2018-07-17End: 2021-08-01Target: 40Updated: 2018-08-17

Related Papers

Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study
The Oncologist2024-07-112 citations
A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED)
Frontiers in Oncology2022-06-0317 citations
Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
2020-11-1513 citations
Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study.
2017-12-2212 citations
Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial
Oncotarget2017-09-2831 citations
Nab-paclitaxel plus S-1 as first-line treatment in patients with advanced pancreatic adenocarcinoma.
Journal of Clinical Oncology2017-05-20
A phase II study of Chinese patients (pts) treated with <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC).
Journal of Clinical Oncology2016-02-012 citations